Indian Company Moves To Provide Affordable Insulin Biosimilar In Europe As Patents Rise 19/10/2016 by Tatum Anderson for Intellectual Property Watch Leave a Comment Bangalore-based Biocon may become the first Indian company to offer a biosimilar insulin in Europe. And the patent and pricing story is interesting.
WIPO Wants Its Pro Bono Patent Lawyer Scheme To Aid Developing Countries’ Inventors 18/10/2016 by Peter Kenny for Intellectual Property Watch Leave a Comment Imagine you’re an inventor in the Philippines and want to file a patent for, say, a fishing implement you’ve invented, but your $9,000 a year income thwarts your ability to pay the legal fees to register it and develop it commercially. You could be stumped from the start.
FTC Recommends Legislative Fixes For Nuisance Patent Lawsuits But Some Question Study 17/10/2016 by Dugie Standeford for Intellectual Property Watch 1 Comment LONDON — Procedural and substantive legislative reforms are needed to keep nuisance patent infringement lawsuits at bay, the United States Federal Trade Commission said in an October report. The question is whether the size of the study on activities of “patent assertion entities” (PAEs) was large enough to prove there’s a problem, say some patent attorneys, including speakers at the 13-14 October London IP Summit.
EU Patent Court Launch Uncertain But Will Happen, Says Preparatory Committee Chief 13/10/2016 by Dugie Standeford for Intellectual Property Watch 1 Comment LONDON — Britain’s vote to leave the European Union is just another “speed bump” along the path to a European unified patent and patent court, the head of the committee tasked with preparing the way for the new system said during a lively session at the 13 October London IP Summit. Others aren’t so sure, since Brexit has raised many complex questions, not least of which is whether there is the political will in the UK or EU to move ahead.
New MedsPaL Database: Enhancing Transparency In The Patent Field 07/10/2016 by Alexandra Nightingale for Intellectual Property Watch 1 Comment A new database was launched this week to facilitate navigation through the patent field and increase transparency surrounding the patent status of medicines and licences.
Partial Revocation Of EPO Patent On Sofosbuvir, Key For Hepatitis C 05/10/2016 by Intellectual Property Watch 4 Comments Following a public hearing at its headquarters in Munich, the European Patent Office (EPO) decided to reject in part the arguments made by Gilead Sciences to uphold their patent on sofosbuvir, according to a non-profit group.
Despite Ongoing Efforts, USPTO Still Faces Patent Quality Issues 16/09/2016 by Dugie Standeford for Intellectual Property Watch 2 Comments The US Patent and Trademark Office continues to face claims of low patent quality despite a major initiative to address the situation. The agency has been the subject of several critical reports by oversight agencies and recently defended its patent quality improvements before Congress. Patent practitioners say that while patent quality may not actually have worsened over the past few years, the USPTO’s ongoing lack of financial and other resources, and inconsistent judicial decisions, are among the factors causing problems.
Switzerland Champions Disclosure Requirement In Patents, Counters US Interpretation 15/09/2016 by Catherine Saez, Intellectual Property Watch 1 Comment The government of Switzerland has issued a defence of its national law on disclosure of origin of genetic resources in patent applications, finding fault with the interpretation of its law by the United States. The Swiss response comes on the eve of a World Intellectual Property Organization meeting on related issues.
Access And Benefit Sharing Mentioned In US Patent For Natural Dye, Might Be A First 01/09/2016 by Catherine Saez, Intellectual Property Watch 2 Comments A recent patent granted by the United States Patent and Trademark Office to a Colombian company stated where the genetic resource of the invention was taken from and described the access and benefit-sharing agreement made with indigenous communities. This might be the first time that such a statement appears in a US patent, according to a source.
The Downfall Of Invention: A Broken Patent System 18/08/2016 by Intellectual Property Watch 1 Comment The cost of dozens of brand-name drugs have nearly doubled in just the past five years. Public outrage over drug prices extends from Capitol Hill to the presidential candidates to patients. In response, pharmaceutical executives are spending more on lobbying and marketing. Yet for all this attention, most of the proposed solutions for reducing prescription drug costs—tougher negotiations, appeals for transparent R&D costs or investigations into insurers—miss one of the primary sources of the problem: the way we award patents, writes Tahir Amin.